A Grand View Research report projects that the global stem cell market will reach $18.4 billion by 2028, with adult stem cells accounting for the largest share.
Over a decade ago, the stem cell research company landscape was much different and narrower than it is today. Investors of the past may remember once-popular companies such as Advanced Cell Technology (ACTC), which was headed by famed scientist, author, and researcher Dr. Robert Lanza, being featured by major media outlets.
Other popular companies included Bioheart, Inc. (BHRT) and tickers like BCLI, CBAI, CCEL, CELG, ISCO, and many more. Reading this may be nostalgic for some readers who remember browsing through Yahoo Finance message boards and following Stem Cell Tracker during the early 2000s.
Today, the landscape has changed a bit. Some companies went bankrupt, others were acquired, and larger market cap players entered into the biotechnology field.
Below is a list of modern public stem cell research companies in alphabetical order:
- Amgen, Inc. ($AMGN)
- ARK ETF Trust ($ARKG)
- Athersys, Inc. ($ATHX)
- Baxter International, Inc. ($BAX)
- BioLine RX Ltd ($BLRX)
- BioMarin Pharmaceutical, Inc. ($BMRN)
- BioNTech SE ($BNTX)
- Biostage, Inc.($BSTG)
- Brainstorm Cell Therapeutics Inc. ($BCLI)
- Celldex Therapeutics, Inc. ($CLDX)
- CRISPR Therapeutics AG ($CRSP)
- Geron Corporation ($GERN)
- Gilead Sciences, Inc. ($GILD)
- Intellia Therapeutics, Inc. ($NTLA)
- Lineage Cell Therapeutics Inc. ($LCTX)
- Mesoblast Ltd. ($MESO)
- Moderna, Inc. ($MRNA)
- Organovo Holdings, Inc. ($ONVO)
- Sanofi ($SNY)
- U.S. Stem Cell, Inc. ($USRM)
- Vertex Pharmaceuticals Incorporated ($VRTX)
- VistaGen Therapeutics, Inc. ($VTGN)
Disclaimer: StemCellTracker.com is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. StemCellTracker.com may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser.